DI-UMONS : Dépôt institutionnel de l’université de Mons

Recherche transversale
Rechercher
(titres de publication, de périodique et noms de colloque inclus)
2017-03-07 - Colloque/Présentation - poster - Anglais - 1 page(s)

Andre Séverine , Daldal Fatima, Delcroix Marie, Muller Robert , Vander Elst Luce , Laurent Sophie , Burtea Carmen , "Targeting phospholipase A2 for the treatment of Alzheimer’s disease through a peptidic modulation" in MDC : Mardi des Chercheurs 2017, Mons, Belgique, 2017

  • Codes CREF : Histologie (DI3212), Sciences biomédicales (DI3200), Biochimie pharmaceutique (DI3491), Biologie moléculaire (DI3111), Neuropathologie (DI332C), Biologie cellulaire (DI311D)
  • Unités de recherche UMONS : Chimie générale, organique et biomédicale (M108)
  • Instituts UMONS : Institut des Sciences et Technologies de la Santé (Santé), Institut des Biosciences (Biosciences)
  • Centres UMONS : Centre de Recherche en Microscopie et Imagerie Médicale (CMMI)

Abstract(s) :

(Anglais) In the highlight of actual management of Alzheimer’s disease (AD), we developed a therapeutic approach including peptides able to modulate an isoform of phospholipase A2, a key enzyme in this pathology, and to cross the blood-brain barrier (BBB) using LDL receptor (LDLr). We showed the ability of our phospholipase A2-targeted peptide to inhibit this enzyme, revealed by a decreased release of arachidonic acid, while the LDLr-targeted peptide, after coupling to nanoparticles, was found in brains of injected mice, confirming its potential as vector through the BBB. We will couple these two peptides to increase the brain access and improve the therapeutic efficacy in vivo.